Phase 3 N=1,800 ACTIV-6: COVID-19 Study of Repurposed Medications
Covid19
Primary: Total Number of Participants Randomized Within Each Appendix — 1800; 1331; 1407; 1459 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=412 A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
Dravet Syndrome · Lennox Gastaut Syndrome · Epileptic Encephalopathy
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 75.5 percentage of participants
Phase 3 N=110 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
Hereditary Angioedema · HAE
Primary: The Mean Acute Angioedema Attack Rate — 0.675; 0.589; 0.593 Confirmed attacks per week
Phase 3 N=310 HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262
Amyotrophic Lateral Sclerosis
Primary: Disease Progression as Assessed by the ALSFRS-R-Slope — -1.00; -0.91; -0.95 Points per month
Phase 3 N=204 A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
Prurigo
Primary: WI-NRS4 Response at Week 12 — 20.6; 44.6 percentage of participants — p=0.0003
Phase 3 N=434 Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
Neovascular Age-related Macular Degeneration
Primary: Evaluate and Compare Functional Changes in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at Week 8 of Treatment With…
Phase 3 N=739 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
Metastatic Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1% — 19.4; 23.5 Months — p=0.8335
Phase 3 N=595 A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
Triple Negative Breast Neoplasms
Primary: Overall Survival (OS) in PD-L1-positive Population — 11.24; 12.09 months — p=0.5891
Phase 3 N=562 An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
Relapsing Multiple Sclerosis
Primary: Annualized Relapse Rate (ARR) — 0.06 relapses/ participant-year — p=<0.0001
Phase 3 N=101 A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
Schizophrenia
Primary: Percentage of Participants Who Discontinued From the Study Due to Clinical Reasons — 7.9 percentage of participants
Phase 3 N=620 Healthy Eating and Active Living Taught at Home (HEALTH) Dissemination & Implementation (D&I)
Obesity
Primary: Change in Weight — -0.24; 0.49 Kg
Phase 3 N=75 An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs) — 28 Participants
Phase 3 N=325 An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Early Alzheimer's Disease
Primary: Primary Cognitive Efficacy Endpoint (ADAS-Cog13) — 4.40; 3.89 Score on a scale — p=0.6058
Phase 3 N=65 Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
Anemia · Iron-deficiency
Primary: Change in Hemoglobin Concentration — 17.7; 12.5; 11.5 g/L
Phase 3 N=16,349 To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
SARS-CoV-2 Infection · COVID-19
Primary: SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim…